• Je něco špatně v tomto záznamu ?

The Cdh5-CreERT2 transgene causes conditional Shb gene deletion in hematopoietic cells with consequences for immune cell responses to tumors

Q. He, X. Li, K. Singh, Z. Luo, M. Meija-Cordova, M. Jamalpour, B. Lindahl, V. Kriz, R. Vuolteenaho, M. Ulvmar, M. Welsh,

. 2019 ; 9 (1) : 7548. [pub] 20190517

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028906

The tamoxifen-responsive conditional Cdh5-CreERT2 is commonly used for endothelial cell specific conditional deletion of loxP-flanked gene sequences. To address the role of endothelial cell Shb gene for B16F10 melanoma immune responses, tamoxifen-injected Cdh5-CreERT2/WT and Cdh5-CreERT2/Shbflox/flox mice received subcutaneous tumor cell injections. We observed a decrease of tumor myeloid cell Shb mRNA in the tamoxifen treated Cdh5-CreERT2/Shbflox/flox mice, which was not present when the mice had undergone a preceding bone marrow transplantation using wild type bone marrow. Differences in CD4+/FoxP3+ Tregs were similarly abolished by a preceding bone marrow transplantation. In ROSA26-mTmG mice, Cdh5-CreERT2 caused detectable floxing in certain bone marrow populations and in spleen cells. Floxing in bone marrow could be detected two months after tamoxifen treatment. In the spleen, however, floxing was undetectable two months after tamoxifen treatment, suggesting that Cdh5-CreERT2 is operating in a non-renewable population of hematopoietic cells in this organ. These data suggest that conditional gene deletion in hematopoietic cells is a potential confounder in experiments attempting to assess the role of endothelial specific effects. A cautious approach to achieve an endothelial-specific phenotype would be to adopt a strategy that includes a preceding bone marrow transplantation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028906
003      
CZ-PrNML
005      
20210114155317.0
007      
ta
008      
210105s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-019-44039-z $2 doi
035    __
$a (PubMed)31101877
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a He, Qi $u Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
245    14
$a The Cdh5-CreERT2 transgene causes conditional Shb gene deletion in hematopoietic cells with consequences for immune cell responses to tumors / $c Q. He, X. Li, K. Singh, Z. Luo, M. Meija-Cordova, M. Jamalpour, B. Lindahl, V. Kriz, R. Vuolteenaho, M. Ulvmar, M. Welsh,
520    9_
$a The tamoxifen-responsive conditional Cdh5-CreERT2 is commonly used for endothelial cell specific conditional deletion of loxP-flanked gene sequences. To address the role of endothelial cell Shb gene for B16F10 melanoma immune responses, tamoxifen-injected Cdh5-CreERT2/WT and Cdh5-CreERT2/Shbflox/flox mice received subcutaneous tumor cell injections. We observed a decrease of tumor myeloid cell Shb mRNA in the tamoxifen treated Cdh5-CreERT2/Shbflox/flox mice, which was not present when the mice had undergone a preceding bone marrow transplantation using wild type bone marrow. Differences in CD4+/FoxP3+ Tregs were similarly abolished by a preceding bone marrow transplantation. In ROSA26-mTmG mice, Cdh5-CreERT2 caused detectable floxing in certain bone marrow populations and in spleen cells. Floxing in bone marrow could be detected two months after tamoxifen treatment. In the spleen, however, floxing was undetectable two months after tamoxifen treatment, suggesting that Cdh5-CreERT2 is operating in a non-renewable population of hematopoietic cells in this organ. These data suggest that conditional gene deletion in hematopoietic cells is a potential confounder in experiments attempting to assess the role of endothelial specific effects. A cautious approach to achieve an endothelial-specific phenotype would be to adopt a strategy that includes a preceding bone marrow transplantation.
650    _2
$a zvířata $7 D000818
650    _2
$a CD antigeny $x genetika $7 D015703
650    _2
$a transplantace kostní dřeně $7 D016026
650    _2
$a kadheriny $x genetika $7 D015820
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x genetika $7 D049109
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a endoteliální buňky $x cytologie $7 D042783
650    12
$a delece genu $7 D017353
650    _2
$a transplantace hematopoetických kmenových buněk $7 D018380
650    _2
$a hematopoetické kmenové buňky $x cytologie $7 D006412
650    _2
$a melanom experimentální $x genetika $x imunologie $7 D008546
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a myši transgenní $7 D008822
650    _2
$a patologická angiogeneze $x genetika $7 D009389
650    _2
$a protoonkogenní proteiny $x genetika $7 D011518
650    _2
$a tamoxifen $x farmakologie $7 D013629
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Li, Xiujuan $u Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden. Cyrus Tang Hematology Center, Soochow University, Suzhou, China.
700    1_
$a Singh, Kailash $u Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
700    1_
$a Luo, Zhengkang $u Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
700    1_
$a Meija-Cordova, Mariela $u Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
700    1_
$a Jamalpour, Maria $u Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
700    1_
$a Lindahl, Björn $u Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.
700    1_
$a Kriz, Vitezslav $u Institute of Molecular Genetics of the CAS, Prague, Czech Republic.
700    1_
$a Vuolteenaho, Reetta $u Transgenic Animals Facility, Oulu University, Oulu, Finland.
700    1_
$a Ulvmar, Maria $u Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
700    1_
$a Welsh, Michael $u Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden. Michael.welsh@mcb.uu.se.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 9, č. 1 (2019), s. 7548
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31101877 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114155316 $b ABA008
999    __
$a ok $b bmc $g 1609241 $s 1120086
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 9 $c 1 $d 7548 $e 20190517 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace